Article
Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.
Cancer research - 15 Aug 2012
Lenos Kristiaan, Grawenda Anna M, Lodder Kirsten, Kuijjer Marieke L, Teunisse Amina F A S, Repapi Emmanouela, Grochola Lukasz F, Bartel Frank, Hogendoorn Pancras C W, Wuerl Peter, Taubert Helge, Cleton-Jansen Anne-Marie, Bond Gareth L, Jochemsen Aart G
Abstract excerpt
Conventional high-grade osteosarcoma is the most common primary bone malignancy. Although altered expression of the p53 inhibitor HDMX (Mdmx/Mdm4) is associated with cancer risk, progression, and outcome in other tumor types, little is known about its role in osteosarcoma. High expression of the Hdmx splice variant HDMX-S relative to the full-length transcript (the HDMX-S/HDMX-FL ratio) correlates with reduced...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.